Genmab A/S is a biopharmaceutical company based in Hovedstaden, Denmark.

Stoke Therapeutics, Inc., reported today key points from presentations pertaining to the continued clinical research of STK-001.

This article summarized the latest R&D progress of Savolitinib, the Mechanism of Action for Savolitinib, and the drug target R&D trends for Savolitinib.

AChE inhibitors function by reversibly inhibiting AChE, leading to the accumulation of ACh at synaptic locations, which in turn improves cognitive functions in Alzheimer's disease (AD) patients.

ILiAD Biotechnologies, LLC, a biotech firm in the clinical trial phase, which is spearheading the creation of an unparalleled, progressive pertussis vaccine, reports promising preliminary results from the CHAMPION-1 clinical trial.

The therapeutic effects among the first generation of 5-HT3 receptor antagonists have no significant differences.

Novo Nordisk is vigorously pursuing the rollout of the obesity medication, Wegovy, across Europe, despite grappling with supply chain issues.

Genentech, Inc. is a renowned organization in the field of biomedicine, specializing in the development of innovative pharmaceutical products.

This article summarized the latest R&D progress of Pralsetinib, the Mechanism of Action for Pralsetinib, and the drug target R&D trends for Pralsetinib.

Zenas BioPharma disclosed today their signing of a licensing and partnership contract with Bristol Myers Squibb Company.

AHR agonists have shown effects in some representative models of autoimmune diseases (including systemic lupus erythematosus, Behcet's syndrome, multiple sclerosis, inflammatory bowel disease, etc.)

Genmab A/S and Seagen Inc.  revealed that its main objective of overall survival when TIVDAK®(tisotumab vedotin-tftv) was used in comparison to chemotherapy only.